^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    12d
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | N=241 --> 366
    Enrollment change
    17d
    Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid (clinicaltrials.gov)
    P=N/A, N=917, Completed, Scripps Translational Science Institute | Enrolling by invitation --> Completed
    Trial completion
    19d
    Efficacy and safety of combination therapy with eravacycline versus the Best Available Treatment in patients with severe infection in the department of hematology: a multicenter retrospective study (ChiCTR2600120570)
    P=N/A, N=350, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    19d
    Deuremidevir Hydrobromide Tablets (VV116) Clinical Application Demonstration Project for the Treatment of SARS-CoV-2 Infection (ChiCTR2600120129)
    P=N/A, N=3347, Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center
    New trial
    28d
    Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers (clinicaltrials.gov)
    P1, N=24, Recruiting, Traws Pharma, Inc.
    New P1 trial
    28d
    GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
    GV1001 administered alone or in combination with cisplatin produced antitumor effects. Collectively, these findings demonstrate that GV1001 functions as a potent immunomodulatory anticancer peptide that downregulates CD47 expression and restores macrophage-mediated tumor clearance, highlighting its potential as a therapeutic strategy for OSCC.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • CD47 (CD47 Molecule)
    |
    cisplatin • LucaVax (tertomotide)
    1m
    A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children (clinicaltrials.gov)
    P3, N=498, Recruiting, Simcere Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model (clinicaltrials.gov)
    P2, N=165, Not yet recruiting, Traws Pharma, Inc.
    New P2 trial
    1m
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=241, Recruiting, Airway Therapeutics, Inc.
    New P2/3 trial
    2ms
    Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gilead Sciences | N=400 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    2ms
    A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect of Single Ascending Doses of TRX-100 in Healthy Volunteers (ACTRN12626000272392)
    P1, N=16, Not yet recruiting, Traws Pharma, Inc
    New P1 trial
    2ms
    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function (clinicaltrials.gov)
    P1, N=30, Recruiting, Aligos Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open